Key points are not available for this paper at this time.
e20138 Background: Treatment options are limited for EGFR-TKIs-resistant advanced NSCLC. A retrospective study from our center showed that ICIs plus platinum-free, single-agent chemotherapy provided progression-free survival, overall response rate benefit, and a low rate of severe AEs in such pts. Meanwhile,there were many NSCLC patients after treatment failure with EGFR-TKIs who ECOG performance status was 2 ,they were excluded from existing prospective studies. This study was designed to further explore the efficacy and safety of Tis plus nab- paclitaxel and Beva foradvancedNSCLCpts with ECOG ps 0-2 failed to EGFR-TKIs. Methods: This is a single-arm, phase II study (NCT04310943). Pts with EGFR mutations who had failed to prior EGFR-TKIs accepted Tis (200mg, d1) ,nab-paclitaxel (100mg/m 2 , d1,8,15) and Beva (15mg/kg, d1) Q3W for up to 4 cycles, followed by Tis plus Beva (7.5mg/kg) maintenance therapy. Primary endpoints are 6m-PFS% and safety, secondary endpoints include ORR and 1-year OS rate. The planned sample size was 24 with unacceptable control of 25%, an expected value of 55%, a one-sided α of 0.05, and a power of 80%, Simon's two-stage design. Results: The median age was 57 (range: 30-70). Thirteen pts (54.2%) harbored EGFR exon 19del and 9 pts (37.5%) had exon 21 L858R at the initial diagnosis. There were 9 pts (37.5%) with ECOG ps 2 and18 pts (75%) with clinical stage IVB. Twelve pts (50%) had stable brain metastases. Fifteen pts (63.6%) progressed on both 1st/2nd and 3rd EGFR-TKIs. As of Dec30, 2023, The median follow-up time was 22.2 m (95%CI 0-51.1). Among the 21pts in the efficacy analysis set, the median PFS was 6.3 m(95%CI 5.5-7.1), the 6m-PFS % was 61.6%, the 6m-PFS% of pts with ECOG ps 2 was18.1%. The ORR was 61.9%, the median DOR was 4.4 m (95%CI 2.1-6.7), DCR was 100.0%. The median OS was 15.4 (95%CI 10.1-20.7) and 1y-OS% was 59.7%. The safety was manageable: the incidence of ≥grade 3 TRAE was 25%. Conclusions: Tislelizumab combined with nab-paclitaxel plus bevacizumab is effective with a manageable safety profile for EGFR-TKIs resistant NSCLC patients with ECOG ps 0-2. Clinical trial information: NCT04310943 . Table: see text
Xiaohong et al. (Sat,) studied this question.